384 results
Page 4 of 20
8-K
EX-99.1
o7bh0rxe1ns5 casri
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-10.2
ck759wdvcl
24 Nov 21
Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
8:20am
8-K
EX-10.1
zh63rxw4 1i1e
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-10.2
saulcwl2jrng0j
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-4.1
erh9zyls7hrnvd
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-10.1
c1w1ahn3
17 Jun 21
Termination of a Material Definitive Agreement
4:14pm
8-K
zoxqiet 51l3fqchbq
17 Jun 21
Termination of a Material Definitive Agreement
4:14pm
8-K
EX-1.1
8hl1lv83p50mpofofxg
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
8-K
EX-5.1
tkowwluo05pc
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
8-K
EX-99.1
5pkxl
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
9lmghli ey8gg
21 May 21
Prospectus supplement for primary offering
12:00am
8-K
ux10gm8i6igxvcj
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
424B5
sq909
19 May 21
Prospectus supplement for primary offering
4:08pm
S-8
EX-5.1
mb8f7ukppj kdjcq
30 Apr 21
Registration of securities for employees
12:00am